Protocol for the development and validation of a risk score to predict risk of adverse events associated with systemic anti-cancer treatment in late-stage lung cancer: Lung Cancer Improved Decisions (LUCID).

IF 3.9
Ofran Almossawi, Luke Steventon, Ruth Keogh, Karla Diaz-Ordaz, Zhe Wang, Andrew Challenger, David Dodwell, Martin Forster, Kenneth K C Man, Li Wei, Sebastian Masento, Adam Januszewski, Pinkie Chambers
{"title":"Protocol for the development and validation of a risk score to predict risk of adverse events associated with systemic anti-cancer treatment in late-stage lung cancer: Lung Cancer Improved Decisions (LUCID).","authors":"Ofran Almossawi, Luke Steventon, Ruth Keogh, Karla Diaz-Ordaz, Zhe Wang, Andrew Challenger, David Dodwell, Martin Forster, Kenneth K C Man, Li Wei, Sebastian Masento, Adam Januszewski, Pinkie Chambers","doi":"10.1186/s41512-026-00225-y","DOIUrl":null,"url":null,"abstract":"<p><p>BACKGROUND: Less than 20% of patients diagnosed with advanced lung cancer will survive beyond five years and half of these will suffer a serious adverse event (SAE) caused by systemic anticancer therapy (SACT) that will result in a hospital attendance. As multiple different SACT treatments are available for patients, a risk score that predicts the likelihood of a SAE following each type of SACT treatment would improve both communication with the patient and shared decision making with all those involved in delivering care for patients. There are currently no risk scores available for use in those with advanced stage lung cancer. AIM: The overarching aim of this research is to develop and internally validate a risk score that will calculate the individualised risk of SAEs for different SACT treatments for patients with late stage lung cancer. METHODS: Utilising linked cancer registry data (National Cancer Registration and Analysis Service (NCRAS), England) for over 20,000 late stage lung cancer patients, a risk score will be developed using a multivariable logistic regression model to predict the risk of an acute admission within 30 days of SACT administration. Model performance will be summarised using calibration and discrimination. Internal validation will be used to quantify the degree of optimism due to overfitting, using re-sampling bootstrapping. Heterogeneity will be assessed, and the model will be fine-tuned. Fine-tuning and interrogation will be used to evaluate differences in performance between hospitals. The clinical utility will be assessed through calculating the net benefit in preventing SAEs. CONCLUSION: A developed risk score (under each treatment strategy) has real potential to support individualised treatment decisions and optimise management of SACT-induced SAEs for patients and reduce hospital attendances. </p>","PeriodicalId":72800,"journal":{"name":"Diagnostic and prognostic research","volume":"10 1","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13059176/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diagnostic and prognostic research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41512-026-00225-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND: Less than 20% of patients diagnosed with advanced lung cancer will survive beyond five years and half of these will suffer a serious adverse event (SAE) caused by systemic anticancer therapy (SACT) that will result in a hospital attendance. As multiple different SACT treatments are available for patients, a risk score that predicts the likelihood of a SAE following each type of SACT treatment would improve both communication with the patient and shared decision making with all those involved in delivering care for patients. There are currently no risk scores available for use in those with advanced stage lung cancer. AIM: The overarching aim of this research is to develop and internally validate a risk score that will calculate the individualised risk of SAEs for different SACT treatments for patients with late stage lung cancer. METHODS: Utilising linked cancer registry data (National Cancer Registration and Analysis Service (NCRAS), England) for over 20,000 late stage lung cancer patients, a risk score will be developed using a multivariable logistic regression model to predict the risk of an acute admission within 30 days of SACT administration. Model performance will be summarised using calibration and discrimination. Internal validation will be used to quantify the degree of optimism due to overfitting, using re-sampling bootstrapping. Heterogeneity will be assessed, and the model will be fine-tuned. Fine-tuning and interrogation will be used to evaluate differences in performance between hospitals. The clinical utility will be assessed through calculating the net benefit in preventing SAEs. CONCLUSION: A developed risk score (under each treatment strategy) has real potential to support individualised treatment decisions and optimise management of SACT-induced SAEs for patients and reduce hospital attendances.

开发和验证预测晚期肺癌系统性抗癌治疗相关不良事件风险的风险评分方案:肺癌改进决策(LUCID)。
背景:诊断为晚期肺癌的患者中,不到20%的患者存活超过5年,其中一半将遭受由全身抗癌治疗(SACT)引起的严重不良事件(SAE),导致住院。由于患者可使用多种不同的SACT治疗,因此风险评分可以预测每种SACT治疗后发生SAE的可能性,这将改善与患者的沟通,并与所有参与患者护理的人员共同做出决策。目前尚无可用于晚期肺癌患者的风险评分。目的:本研究的总体目标是开发并内部验证一个风险评分,该评分将计算晚期肺癌患者不同SACT治疗的个体化SAEs风险。方法:利用超过20,000名晚期肺癌患者的相关癌症登记数据(英国国家癌症登记和分析服务(NCRAS)),将使用多变量logistic回归模型开发风险评分,以预测SACT给药后30天内急性入院的风险。模型性能将使用校准和判别来总结。内部验证将用于量化由于过度拟合的乐观程度,使用重新采样引导。异质性将被评估,模型将被微调。微调和审讯将用于评估医院之间的表现差异。临床效用将通过计算预防SAEs的净收益来评估。结论:开发的风险评分(在每种治疗策略下)具有支持个性化治疗决策和优化sact诱导的SAEs管理的真正潜力,并减少住院率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
18 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书